Recently, immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have shown promise in solid and hematological tumors by blocking co-inhibitory signals and enhancing CD8+ T cell-mediated tumor destruction [17]. Here, CD8A is linked to neoplasm.